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Abstract
Transduction of T cells with a chimeric immune T cell receptor (CIR) has been proposed as a strategy to generate cellular immunity
against viral pathogens such as HIV-1. In the case of the CD4-CD3- chain (CD4-) CIR, specificity for HIV-1 is conferred by binding of
the CD4 moiety to gp120 on the surface of infected cells. However, it is unclear whether CD4--T cells may differ from naturally derived
CD8 cytotoxic T cells (CTL) in their susceptibility to viral escape mechanisms or ability to recognize different cell types that support viral
replication. We demonstrate that CIR-T cells can mediate antiviral activity against HIV-1 in cells that are resistant to class I-restricted
CTL-mediated activity. Furthermore, CIR-T cells can suppress virus in multiple cell types, including monocytes, dendritic cells, and
lymphocyte-dendritic cell clusters. These results provide evidence that T cells can be redirected against novel targets, and that independence
from the class I pathway may have distinct advantages.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Cellular immunity has important roles in viral and tumor
immunology. CD8 effector T cells, cytotoxic T lympho-
cytes (CTL), are capable of specifically recognizing and
killing cells expressing abnormal proteins, and therefore are
believed to mediate clearance of cells infected with viruses
or expressing abnormal regulatory proteins leading to on-
cogenic transformation. The specificity of CTL is conferred
by the T cell receptor (TCR), which is an immunoglobulin-
like surface molecule directed against a foreign peptide
presented by a major histocompatibility class I molecule on
the target cell surface (reviewed in Eisen et al., 1996).
Recognition of the target cell and triggering of the CTL to
kill is therefore restricted by both the presented peptide
sequence and the class I allele.
Most cells express surface class I molecules, which
present peptide fragments of proteins being produced within
the cell for surveillance by CTL. The process of class
I-mediated peptide presentation involves proteolysis of
newly translated proteins by the proteasome, transportation
of peptide fragments into the rough endoplasmic reticulum
(RER) by the TAP complex, binding of peptides to nascent
class I molecules in the RER, and presentation of the pep-
tide-MHC complexes on the cell surface (Eisen et al., 1996).
Given the necessity of this complex pathway for recognition
of infected or abnormal cells by CTL, viruses (Collins and
Baltimore, 1999; Koup, 1994; Powis, 1998) and tumor cells
(Costello et al., 1999; Marincola et al., 2000) have evolved
mechanisms to interrupt this process.
We have demonstrated previously (Yang et al., 1997b)
that CD8 T cells transduced with a recombinant T cell
receptor have potent activity against HIV-1 infected cells in
vitro. This study examined T3F3 cells, which have been
transduced with a chimeric T cell receptor (CIR) containing
the human CD4 molecule spliced to the  chain signaling
domain of the CD3 complex (CD4-), rendering T3F3 cy-
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tolytic for HIV-1-infected cells through binding of the CIR
to HIV-1 gp120 on the infected cell surface (Roberts et al.,
1994). Administration of CIR-transduced cells in vivo has
been considered a potential strategy for generating virus-
specific CD8 T cells, since naturally occurring MHC class
I-restricted CD8 cytotoxic T lymphocytes (CTL) are be-
lieved to have an important role in the control of HIV-1
infection (reviewed in Yang and Walker, 1997).
Because CIR-T cells interact with infected cells through
a non-physiologic mechanism, it is not clear whether they
have the same properties as naturally generated HIV-1-
specific CTL. The ability to recognize cells independently
of antigen processing could be advantageous in bypassing
viral escape mechanisms that modulate the class I pathway,
but varying levels of gp120 expression or other factors
specific to non-lymphocyte cell types could limit the activ-
ity of CIR-T cells. We therefore examine further the anti-
viral function of HIV-1-specific CIR-T cells.
Results
CIR-CTL perform effector functions independently of the
class I pathway
Because a common mechanism of immune evasion of
CTL is interference with the class I pathway, we evaluated
the ability of naturally-derived HIV-1-specific CTL and
CIR-CTL to suppress HIV-1 system in cells that are defec-
tive in presentation of class I antigens. Acutely HIV-1-
infected T1 cells, and derivative T2 cells that are deficient in
TAP and therefore incapable of transporting class I antigens
from the proteasome (Salter and Cresswell, 1986), were
co-cultured with an HIV-1-specific CTL clone (68A62),
control CD8 T cells from an uninfected individual (T3), or
CD4--transduced CIR-T cells (T3F3). As we previously
observed for T1 cells (Yang et al., 1997b), CTL and CIR-T
cells, but not untransduced control cells, were inhibitory for
viral replication in T1 cells by orders of magnitude (Fig.
1A). In contrast, 68A62 was unable to inhibit replication in
the TAP-deficient cell line T2, whereas T3F3 cells remained
inhibitory (Fig. 1B).
In four independent experiments with naturally derived
CTL clones (five clones recognizing A2- and B60-restricted
epitopes in Gag, RT, and Nef), the clones suppressed viral
replication by 2.9  1.1 (mean  1 S.D.) log10 units in T1
cells, but 0.2  0.3 log10 units in T2 cells (P  0.00001)
(not shown). In two independent experiments with T3F3,
viral replication was suppressed by 3.7  0.3 log10 units in
T1 cells and 3.0  0.4 log10 units in T2 cells (P  0.20),
with the negative control T3 cells inhibiting 0.2  0.2 and
0.1  0.1 log10 units in these cells, respectively (not
shown). In sum, these results indicated that interference
with the class I antigen-processing pathway ablates the
antiviral activity of natural CTL, but does not affect the
function of CIR-CTL.
CIR-CTL are active against a broad spectrum of primary
cell types
In parallel to our previous study on whether naturally
derived CTL are able to suppress viral replication in
different primary cell types (Severino et al., 2000), we
examined the ability of T3F3 to suppress viral replication
in primary CD4 lymphocytes, monocytes, dendritic
cells, and dendritic cell/lymphocyte clusters (Fig. 2).
Monocytes (Fig. 2B) and dendritic cells (Fig. 2C) were
less productively infected than lymphocytes (Fig. 2A),
and dendritic cell/lymphocyte clusters (Fig. 2D) were the
most productive, as previously observed (Severino et al.,
2000). However, HIV-1 replication in all cell types was
inhibited by T3F3 cells. Over four experiments for each
cell type, T3F3 cells suppressed viral replication by
(mean  1 S.D.) 2.7  1.1 log10 units in lymphocytes,
3.2  0.8 log10 units in monocytes, 3.4  0.9 log10 units
in dendritic cells, and 2.5  2.0 log10 units in dendritic
cell-lymphocyte clusters (not shown). Suppression in the
dendritic cell/lymphocyte clusters was therefore the least
efficient and consistent as compared to the other cells,
similar to what was previously observed for naturally-
derived CTL clones (Severino et al., 2000). These data
indicated that CIR-CTL can act against several primary
cell types believed to be targets for HIV-1 replication in
vivo.
Fig. 1. Suppression of HIV-1 replication in T1 and T2 cells. T1 cells, or
their TAP-deficient derivative T2 cells, were acutely infected with HIV-1
IIIB and cocultured with T3 (a primary CD8 T cell line from an HIV-1
seronegative donor), T3F3 (T3 transduced with the CD4- chain chimeric
T cell receptor), or 68A62 (an RT-specific A2-restricted CTL clone iso-
lated from an HIV-1-infected individual). At the indicated time intervals,
HIV-1 p24 antigen was assessed. These results are representative of two
experiments with T3 and T3F3, and four experiments with naturally de-
rived CTL clones (68A62 and four others recognizing A2- and B60-
restricted epitopes in Gag, RT, and Nef) (data described in Results, and not
shown).
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Discussion
Chimeric immune receptor-transduced T cells have been
proposed as a potential immunotherapeutic approach for the
treatment of HIV-1 and malignancies. By using a molecule
that binds a cell surface target protein (such as CD4 that can
bind HIV-1 gp120, or the antigen-binding region of an
immunoglobulin molecule) as the external domain of the
chimeric immune receptor, the transduced cells can be se-
lectively targeted against a cell of interest. This may allow
the production of antigen-specific T cells through CIR trans-
duction, able to recognize target cells such as HIV-1 in-
fected T cells (Roberts et al., 1994) or tumor cells (McGuin-
ness et al., 1999; Patel et al., 2000).
Our data suggest that CIR-T cells may functionally differ
from naturally-derived CTL yet maintain the ability to act
on multiple primary different cell types. The independence
of CIR-T cell activity from needing to recognize specific
viral HLA-restricted epitopes may be an advantageous as-
pect of this approach to generating CTL. Epitope point
mutations, epitope antagonism, interference with antigen
processing, and class I downregulation all have been mech-
anisms postulated to allow avoidance of CTL responses in
vivo (Collins and Baltimore, 1999; Koup, 1994; McMichael
and Phillips, 1997). Our data indicate that CIR-T cells
operate in the absence of class I antigen presentation (TAP-
deficiency) in contrast to naturally occurring CTL, as might
be predicted from the mechanism of the CIR. CIR-T cells
are therefore likely to be unaffected by such immune eva-
sion strategies, although rapidly adaptive pathogens such as
HIV-1 may still be able to escape through mutation of the
recognized protein. In fact, CD4-independent strains of
HIV-1 have been generated experimentally (Dumonceaux et
al., 1998; Hoxie et al., 1998), and these would potentially
resist the activity of the CD4- CIR.
In the case of HIV-1, it appears that the Nef protein has
an important role in rendering infected cells relatively re-
sistant to the antiviral effects of CTL (Collins et al., 1998;
Yang et al., 2002). This is believed to be through the ability
of Nef to downregulate the class I molecule from the cell
surface (Collins et al., 1998). We have found that Nef
mediates viral resistance to suppression by naturally-de-
rived CTL, but that CIR-CTL are unaffected and remain
capable of inhibiting HIV-1 (Yang et al., 2002). These data
therefore confirm that CIR-CTL can entirely bypass the
requirement for class I-restricted antigen processing and
presentation, and can counteract immune evasion strategies
such as that mediated by HIV-1 Nef.
Another important property for CTL to be effective is the
ability to clear relevant cell types. For HIV-1, monocytes,
myeloid dendritic cells, and dendritic cell/lymphocyte clus-
ters are believed to be important sites of viral replication in
vivo. The potentially important roles of monocyte/macro-
phages as long-lived viral reservoirs (Perelson et al., 1996)
and myeloid dendritic cells as early transporters of virus in
acute infection (Cameron et al., 1996; Grouard and Clark,
1997; Knight, 1996; Spira et al., 1996; Stahl-Hennig et al.,
1999) prompted analysis of CIR-T cell activity on these
cells. The ability of CIR-T cells to inhibit HIV-1 replication
in all of these cell types indicates that gp120 expression on
these cell types is adequate for recognition and viral control
by CIR-T cells. Our previous work suggested that dendritic
cell/lymphocyte clusters are less susceptible to the antiviral
activity of HIV-1-specific CTL. CIR-T cells also appear to
be less potent against these clusters. This indicates that the
defect is not due to differences in antigen processing or
presentation, but may be a consequence of the more vigor-
ous rate of viral replication due to activation of lymphocytes
by dendritic cells (Cameron et al., 1992; Pope et al., 1994).
The capability of CIR-CTL to act on dendritic cells may
have further implications in their immunotherapeutic appli-
cation. Dendritic cells play a pivotal role in priming new
CTL responses and providing immunologic help for the
maintenance of immunity (Steinman and Inaba, 1999). The
ability of CIR-CTL to interact with dendritic cells suggests
that it may be possible to use dendritic cells to activate and
maintain transduced CIR-CTL.
In summary, we find that CIR-T cells may circumvent
viral cellular immune evasion mechanisms relating to anti-
gen presentation, and are capable of suppressing HIV-1
Fig. 2. Suppression of HIV-1 replication in multiple CD4 primary cell
types. Primary lymphocytes, monocytes, and dendritic cells were acutely
infected with HIV-1 JR-CSF and cocultured with T3 or T3F3, and viral
replication was monitored by p24 antigen measurement. These results are
typical of four experiments comparing each cell type from two donors (data
described in Results, and not shown).
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replication in monocytes, dendritic cells, and monocyte/
dendritic cell clusters. Thus, in comparison to naturally-
derived specific CTL, CIR-T cells may be less susceptible to
immune escape through mechanisms that interfere with
class I antigen presentation, and are capable of acting upon
multiple physiologic cell types.
Materials and methods
Immortalized target cells
HIV-1 permissive T cell lines used for acute infection
included T1 cells, a CD4 lymphoblastoid cell line (Salter,
et al., 1985) expressing HLA A2 (Yang et al., 1997a), and
T2 cells, a derivative of T1 cells deficient in transporter
associated with processing complex (TAP) and therefore
unable to transport antigens through the class I pathway
(Salter and Cresswell, 1986).
Primary target cells
Primary activated CD4 T lymphocytes, monocytes, and
myeloid dendritic cells were generated from peripheral
blood mononuclear cells as previously described (Severino
et al., 2000). In brief, lymphocytes were stimulated with a
CD3:CD8 bispecific antibody (Wong and Colvin, 1987),
monocytes were isolated by adherence selection, and den-
dritic cells were produced by culture of monocytes in IL-4
and GM-CSF. The cell populations were confirmed by flow
cytometry for CD3/CD4 (lymphocytes), CD14 (mono-
cytes), and CD1a/CD80/CD86 (immature dendritic cells).
Effector cells
The RT-specific CTL clone 68A62 (specific for the HLA
A2-restricted reverse transcriptase epitope ILKEPVHGV,
derived from the PBMC of an infected person) and other
HIV-1-specific CTL clones were maintained as previously
described (Yang et al., 1997a). T3F3 was derived by trans-
duction of the CD8 primary T cell line T3 (isolated from
the PBMC of an HIV-1-seronegative individual) with the
CD4- construct (Roberts et al., 1994).
HIV-1 suppression assays
The immortalized T cell lines or primary cells were
acutely infected with HIV-1 IIIB or JR-CSF respectively,
for co-culture assays with CTL as previously described
(Severino et al., 2000; Yang et al., 1997a). 5  105 of the
infected cells were cultured with 1.25 105 effector cells in
a 24 well plate in 2 ml of medium, followed by harvest of
1 ml for quantitative p24 antigen ELISA and medium re-
placement every two to four days. Prior control experiments
indicated that suppression by naturally-derived CTL and
T3F3 in this system is dose-dependent (not shown). Inhibi-
tion after approximately 7 days of coculture in log10 units
was calculated by the formula: log10(p24 with CTL/p24
without CTL).
Statistical comparisons
Student’s t-test (two-tailed) was used to calculate P val-
ues for differences between groups (Excel, Microsoft Cor-
poration).
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